November 16th 2023
Vidofludimus calcium is a potential first-in-class nuclear receptor related 1 (Nurr1) activator and a selective dihydroorotate dehydrogenase (DHODH) inhibitor.
Early Depression Unlikely To Cause More Severe Disability in MS patients, Study Suggests
July 17th 2023Researchers have been working on sorting out the causal direction of multiple sclerosis (MS) and depression. These findings suggest that depression can be a consequences of MS-related disability not the other way around.
Read More
Study Shows Stopping Disease-Modifying Therapy May Be Safe for Older Adults with MS
July 5th 2023The researchers conclude that it is “reasonable option” for older patients with stable multiple sclerosis (MS) to stop taking disease-modifying therapy because the risk of relapse from doing so is small.
Read More
Sexual Dysfunction in Patients with MS Associated with Fatigue and Depression
April 17th 2023Neurologists may feel ill-equipped to manage or identify sexual problems of multiple sclerosis patients, wrote the authors, but it's important they ask patients about sexual function and satisfaction.
Read More
Researchers Develop ‘Mini-Brain’ Model That Could Help Identify Targets for MS Treatment
February 15th 2023Cerebral organoids shed light on cells that generate the myelin cells that protect the axons of neuron. In multiple sclerosis, inflammatory processes attack the myelin of neurons in the brain and spinal cord.
Read More
More People with Multiple Sclerosis to Qualify for ABLE Savings Accounts
February 7th 2023The new law raises the age threshold for the onset of disabling conditions that make people eligible to have the savings accounts. The money in the accounts do not count toward the limits for Medicaid and the Supplemental Nutritional Assistance Program.
Read More